A quiet weekend yields to the workaday week. At least we have playoff baseball to look forward to. While you were setting your rotation ... (will it be Lee or Hamels in game 1 on Wednesday?)- Bloomberg breaks down the uphill battle Boehringer may face when its apparently-successful linagliptin DPP-4 inhibitor hits a diabetes market already familiar with Januvia and Onglyza.
- More good news for Genentech's Lucentis after last week's CMS decision re limiting reimbursement for Avastin in eye disease; full results of two previously reported studies of the drug in retinal vein occlusion show a significant benefit.
- The NYT reports on the sweet science of DIY liquid Tamiflu. Mmmmm, cherry. In other H1N1/swine flu news, the WSJ notes that distributing and administering available vaccine may take quite some time.
- Ex Intermune CEO W. Scott Harkonen convicted of fraud, facing tough sentence.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.